Phase 3 trial evaluating Vectibix vs. Erbitux for the treatment of chemo-refractory metastatic colorectal cancer meets its primary endpoint for overall survival.
Axitinib is a multitargeted TKI indicated for the treatment of advanced RCC after failure of one prior systemic therapy.
Having more comprehensive discussions about colorectal cancer screening with primary care providers (PCPs) is associated with increased odds of screening.
Female smokers have a significantly increased risk of colon cancer, particularly for proximal colon cancer, compared to male smokers.
Adverse events associated with regorafenib are manageable with a proactive strategy that includes prophylactic treatment and education for the patient, caregiver, and healthcare provider, research presented at the ONS 38th Annual Congress has shown.
Combining cetuximab (Erbitux) with standard therapy improved the resectability of previously inoperable liver metastases of colorectal cancer.
Although the absolute risk is low, use of anesthesia for colonoscopy is associated with a somewhat higher frequency of complications.
For elderly patients with metastatic colorectal cancer, certain geriatric scores were predictive of severe toxicity or unexpected hospitalization after fluorouracil-based chemotherapy with or without irinotecan.
Persons with metastatic gastric cancer who had both surgery and radiation lived longer than patients who underwent one or neither treatment.
A recent study uncovered adenoma detection rates significantly higher than those set in national guidelines.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|